SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) is pleased to announce
that the Company's strong intellectual property portfolio has been enhanced by
the addition of a new patent granted in Australia.


This Australian patent, numbered 2002325712 and entitled "Differentiation of
Neural Stem Cells and Therapeutic Use Thereof", protects the combination of
prolactin with agents such as erythropoietin (EPO) or pituitary adenylate
cyclase activating polypeptide (PACAP) for treating patients suffering from a
variety of central nervous system (CNS) disorders including brain injury,
stroke, Alzheimer's disease, multiple sclerosis (MS), Huntington's disease,
amyotrophic lateral sclerosis, Parkinson's disease, and other CNS diseases. The
strategy of using a therapeutic regimen of drugs to produce neuronal or glial
precursor cells, as taught in this patent, has the potential to be a key
treatment for many CNS diseases.


"We are very pleased with the issuance of this patent in Australia as it expands
our international intellectual property coverage for this patent family, adding
to patents previously issued in the US and Japan" said Dr. Alan Moore, President
and CEO of SCT. "Our strong international patent position provides us with a
significant market advantage and incentive to widen our therapeutic scope
initially focused on NTx(TM)-265. As such, we are now assessing the efficacy of
a Prolactin-EPO regimen versus an hCG-EPO regimen in a pre-clinical model of
traumatic brain injury."


About NTx(TM)-265: NTx(TM)-265 is a therapeutic regimen of two approved and
clinically well-defined drugs, human Chorionic Gonadotropin (hCG) and
Erythropoietin (EPO), targeting the treatment of stroke. The objective of the
regimen is to stimulate the growth and differentiation of new neurons to replace
the brain cells that were lost or damaged by the stroke. Animal studies have
shown a significant recovery in motor function after receiving the NTx(TM)-265
regimen 24-48 hours post stroke. Similar results have been found in SCT's Phase
IIa BETAS safety trial, as announced on April 10, 2007. Final results of SCT's
Phase IIa BETAS trial will be released February 2008 at the International Stroke
Conference in New Orleans, LA. SCT has initiated a multi-centre, double-blind,
placebo-controlled Phase IIb REGENESIS study for NTx(TM)-265 with primary
endpoints of efficacy.


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian
public biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The company's programs aim to
repair neurological function lost due to disease or injury. The company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases.


For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024